Axi-cel demonstrated a 90% overall response rate and 75% complete response rate in relapsed/refractory indolent non-Hodgkin lymphoma. Median progression-free survival was 62.2 months, with a median ...

VigenCell, a company specializing in immune cell therapy, is moving toward early commercialization after presenting significant results in Phase 2 ...

Blood Cancer United's new research funding supports foundational science, AI, big data and global collaborations to improve patient outcomes WASHINGTON, Dec. 2, 2025 /PRNewswire/ ...

Mycosis fungoides is the most common subtype, making up the vast majority of CTCL cases. While early-stage disease has an estimated five-year survival rate of 88%, it remains a difficult-to-manage ...

The global follicular lymphoma market is witnessing growth due to advancements in targeted therapies and immunotherapies. Follicular lymphoma, an indolent form of non-Hodgkin lymphoma, often presents ...

Progress in the treatment of T-cell blood cancers – which are rare – has also been modest. So, much remains to be done to ...

(hereinafter referred to as “Juventas”) announced that its independently developed CAR-T cell therapy product, Inaticabtagene Autoleucel (Ina-cel) (tradename: YORWIDATM), has received new drug ...

The FDA’s docket in December includes decisions for two big biologic franchises: BMS’s Breyanzi and Amgen’s Uplizna.

While traditional methods like blood tests and microscopic examination remain important, modern technology offers far greater ...

ASH will recognize Rainer Storb, MD, with the Wallace H. Coulter Award for Lifetime Achievement in Hematology, the society's highest honor. See below for summaries and links to selected Fred Hutch ...

Opdivo (nivolumab), in combination with Yervoy (ipilimumab), is indicated for the treatment of adult and paediatric patients 12 years and older with unresectable or metastatic microsatellite ...

As big pharmas including Takeda and Novo Nordisk flee the cell therapy space and smaller biotechs shutter their operations, ...